BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35383035)

  • 1. Differences in breast cancer diagnosis by patient presentation in Ontario: a retrospective cohort study.
    Habbous S; Homenauth E; Barisic A; Kandasamy S; Majpruz V; Forster K; Yurcan M; Chiarelli AM; Groome P; Holloway CMB; Eisen A
    CMAJ Open; 2022; 10(2):E313-E330. PubMed ID: 35383035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening behaviours, demographics, and stage at diagnosis in the publicly funded Ontario Breast Screening Program.
    Gold N; Christensen RAG; Arneja J; Aminoleslami A; Anderson GM; Brooks JD
    Breast Cancer Res Treat; 2023 Apr; 198(3):523-533. PubMed ID: 36800117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organized breast screening improves reattendance compared to physician referral: a case control study.
    Makedonov I; Gu S; Paszat LF;
    BMC Cancer; 2015 Apr; 15():315. PubMed ID: 25928416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating wait times from screening to breast cancer diagnosis among women undergoing organised assessment vs usual care.
    Chiarelli AM; Muradali D; Blackmore KM; Smith CR; Mirea L; Majpruz V; O'Malley FP; Quan ML; Holloway CM
    Br J Cancer; 2017 May; 116(10):1254-1263. PubMed ID: 28359079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using Real-World Data to Determine Health System Costs of Ontario Women Screened for Breast Cancer.
    Mittmann N; Seung SJ; Diong C; Gatley JM; Wolfson M; Guertin MH; Pashayan N; Simard J; Chiarelli AM
    Curr Oncol; 2022 Oct; 29(11):8330-8339. PubMed ID: 36354717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of organized breast assessment on survival by stage for screened women diagnosed with invasive breast cancer.
    Smith CR; Chiarelli AM; Holloway CM; Mirea L; O'Malley FP; Blackmore KM; Pandya A; Majpruz V; Harris CP; Hendry A; Hey A; Kornecki A; Lougheed G; Maier BA; Marchand P; McCready D; Rand C; Raphael S; Segal-Nadler R; Sehgal N; Muradali D
    Breast; 2018 Oct; 41():25-33. PubMed ID: 29957557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. False-positive result and reattendance in the Ontario Breast Screening Program.
    Chiarelli AM; Moravan V; Halapy E; Majpruz V; Mai V; Tatla RK
    J Med Screen; 2003; 10(3):129-33. PubMed ID: 14561264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic assessment wait time indicators in the High Risk Ontario Breast Screening Program.
    Eisen A; Blackmore KM; Meschino WS; Muradali D; Carroll JC; Majpruz V; Warner E; Rabeneck L; Chiarelli AM
    Mol Genet Genomic Med; 2018 Mar; 6(2):213-223. PubMed ID: 29368425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer detection method, diagnostic interval and use of specialized diagnostic assessment units across Ontario, Canada.
    Jiang L; Gilbert J; Langley H; Moineddin R; Groome PA
    Health Promot Chronic Dis Prev Can; 2018 Oct; 38(10):358-367. PubMed ID: 30303656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer diagnosis and treatment wait times in specialized diagnostic units compared with usual care: a population-based study.
    Webber C; Whitehead M; Eisen A; Holloway CMB; Groome PA
    Curr Oncol; 2020 Aug; 27(4):e377-e385. PubMed ID: 32905256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of screening result on waiting times to assessment and breast cancer diagnosis: results from the Ontario Breast Screening Program.
    Chiarelli AM; Mai V; Halapy EE; Shumak RS; O'Malley FP; Klar NS
    Can J Public Health; 2005; 96(4):259-63. PubMed ID: 16625791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance measures from 10 years of breast screening in the Ontario Breast Screening Program, 1990/91 to 2000.
    Chiarelli AM; Halapy E; Nadalin V; Shumak R; O'Malley F; Mai V
    Eur J Cancer Prev; 2006 Feb; 15(1):34-42. PubMed ID: 16374227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of wait times across the breast cancer treatment pathway among screened women undergoing organized breast assessment versus usual care.
    Blackmore KM; Weerasinghe A; Holloway CMB; Majpruz V; Mirea L; O'Malley FP; Paroschy Harris C; Hendry A; Hey A; Kornecki A; Lougheed G; Maier BA; Marchand P; McCready D; Rand C; Raphael S; Segal-Nadler R; Sehgal N; Muradali D; Chiarelli AM
    Can J Public Health; 2019 Oct; 110(5):595-605. PubMed ID: 31037608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast screening outcomes in women with and without a family history of breast and/or ovarian cancer.
    Halapy EE; Chiarelli AM; Klar N; Knight J
    J Med Screen; 2004; 11(1):32-8. PubMed ID: 15006112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An assessment of the influence of clinical breast examination reports on the interpretation of mammograms in a breast screening program. Ontario Breast Screening Program Radiologists Research Group.
    Knight JA; Libstug AR; Moravan V; Boyd NF
    Breast Cancer Res Treat; 1998 Mar; 48(1):65-71. PubMed ID: 9541190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axillary node dissection in patients with breast cancer diagnosed through the Ontario Breast Screening Program: a need for minimally invasive techniques.
    Singhal H; O'Malley FP; Tweedie E; Stitt L; Tonkin KS
    Can J Surg; 1997 Oct; 40(5):377-82. PubMed ID: 9336528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to guidance for prioritizing higher risk groups for breast cancer screening during the COVID-19 pandemic in the Ontario Breast Screening Program: a descriptive study.
    Chiarelli AM; Walker MJ; Espino-Hernandez G; Gray N; Salleh A; Adhihetty C; Gao J; Fienberg S; Rey MA; Rabeneck L
    CMAJ Open; 2021; 9(4):E1205-E1212. PubMed ID: 34933878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of familial risk and mammography screening on prognostic indicators of breast disease among women from the Ontario site of the Breast Cancer Family Registry.
    Walker MJ; Mirea L; Cooper K; Nabavi M; Glendon G; Andrulis IL; Knight JA; O'Malley FP; Chiarelli AM
    Fam Cancer; 2014 Jun; 13(2):163-72. PubMed ID: 24097051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Sclerosis and the Cancer Diagnosis: Diagnostic Route, Cancer Stage, and the Diagnostic Interval in Breast and Colorectal Cancer.
    Groome PA; Webber C; Maxwell CJ; McClintock C; Seitz D; Mahar A; Marrie RA
    Neurology; 2022 May; 98(18):e1798-e1809. PubMed ID: 35501160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of image quality indicators among mammography facilities in Ontario.
    Ford NL; Yaffe MJ
    Can Assoc Radiol J; 2001 Dec; 52(6):369-72. PubMed ID: 11780545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.